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Summary
 
The lytic activity of natural killer (NK) cells is inhibited by the expression of class I major his-
tocompatibility complex (MHC) antigens on target cells. In murine NK cells, Ly-49A mediates
inhibition of cytotoxicity in response to the class I MHC antigen H-2D
 
d
 
. In this report, we
studied the function of mouse Ly-49A in both the rat NK cell tumor line, RNK-16, trans-
fected with Ly-49A cDNA, and in primary NK cells. We show that ligation of Ly-49A by
H-2D
 
d
 
 inhibits early signaling events during target cell stimulation, including polyphospho-
inositide turnover and tyrosine phosphorylation. We also show that Ly-49A directly associates
with the cytoplasmic tyrosine phosphatase SHP-1, and that Ly-49A function is impaired in NK
cells from SHP-1 mutant viable motheaten mice and from SHP-1–deficient motheaten mice.
Finally, we demonstrate that mutational substitution of the tyrosine within the proposed SHP-1
binding motif in Ly-49A completely abrogates inhibition of NK cell cytotoxicity through this
receptor. These results demonstrate that Ly-49A interrupts early activating signals in NK cells,
and that SHP-1 is an important mediator of Ly-49A function.
 
N
 
K cells and some T cells express a variety of type II
transmembrane receptors characterized by extracellu-
lar C-type lectin domains (1). In mice, these proteins in-
clude the members of the Ly-49 family (2–8), which rec-
ognize MHC class I molecules on target cells (6–10), and
the NKR-P1 family, whose physiologic ligands have yet to
be determined (11–13). While the NKR-P1 molecules ac-
tivate NK cell cytotoxicity (14–16), at least three members
of the Ly-49 family inhibit NK cell function (6–8).
Susceptible targets stimulate phosphoinositide turnover,
calcium mobilization, and the induction of protein tyrosine
phosphorylation in NK cells. These signals have been asso-
ciated with activation of NK cell cytotoxic responses (17–20).
The NKR-P1 lectin-like receptor also transduces these ac-
tivating signals in NK cells (14–16). In contrast, mouse Ly-
49A inhibits NK cell cytotoxicity upon ligation by the tar-
get cell MHC class I molecules H-2D
 
d
 
 or H-2D
 
k
 
 (6, 9, 10).
The mechanisms by which Ly-49A interrupts NK cell acti-
vation are poorly understood, but important clues can be
derived from structural motifs within the Ly-49A molecule.
The Ly-49A cytoplasmic domain contains the amino
acid sequence VxYxxV, which constitutes a proposed bind-
ing motif for the cytoplasmic tyrosine phosphatase, SHP-1
(21, 22). SHP-1 is an SH2 domain containing tyrosine phos-
phatase, expressed in hematopoietic cells that can inhibit spe-
cific cellular functions. SHP-1 negatively modulates signal-
ing through the erythropoietin receptor (23, 24), and it
inhibits activation of B cells through its association with
Fc
 
g
 
RIIB1 (25–28). In human NK cells, SHP-1 has been
implicated in inhibition of cytotoxicity through its associa-
tion with the killer inhibitory receptors (KIRs)
 
1
 
, members of
the Ig family that bind to human MHC class I molecules
(21, 29, 30). The presence of a proposed SHP-1 binding
motif in the cytoplasmic domain of Ly-49A suggests that
this murine receptor may also functionally associate with
SHP-1. A tyrosine-phosphorylated synthetic tridecapeptide
derived from the cytoplasmic domain of Ly-49A has re-
cently been shown to bind to SHP-1 and to the related
phosphatase SHP-2, but the functional relevance of these
findings to intact Ly-49A has not yet been examined (22).
In this report, we demonstrate that ligation of Ly-49A in-
terrupts early signals for NK cell activation, inhibiting ty-
rosine phosphorylation and polyphosphoinositide turnover.
 
1
 
Abbreviations used in this paper:
 
 APT, phosphotyrosine; InsP
 
3
 
, inositol
triphosphates; ITIM, immunoreceptor tyrosine-based inhibitory motif;
KIRs, killer inhibitory receptors; LAK, IL-2-activated NK cells.
  
674
 
Inhibitory Mechanisms of Ly-49A
 
We also demonstrate that intact Ly-49A directly associates
with SHP-1. Moreover, we show that the full inhibitory
effect of Ly-49A in NK cells requires intact SHP-1 func-
tion as well as the tyrosine residue within the proposed
SHP-1 binding site of Ly-49A.
 
Materials and Methods
 
Cells.
 
RNK-16, a spontaneous NK cell leukemia from F344
rats, was the gift of C. Reynolds (National Cancer Institute, Fre-
derick, MD) and was adapted for in vitro growth in RPMI-1640
supplemented with 10% heat-inactivated FCS, 25 
 
m
 
M 2-ME, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin
(complete RPMI) (31). Tumor target cell lines cultured in com-
plete RPMI included YAC-1 (mouse lymphoma, H-2
 
a
 
), P388D1
(mouse macrophage, H-2
 
d
 
), and C1498 (mouse monocyte, H-2
 
b
 
)
from the American Type Culture Collection (Rockville, MD).
D12 (C1498 transfected with H-2D
 
d
 
, C1498.D
 
d
 
), a gift from W.
Yokoyama, was described previously (6). B-16S, a mouse mela-
noma line (H-2
 
b
 
), was a gift from K. Kärre (Karolinska Institute,
Stockholm, Sweden).
 
Mice.
 
Viable motheaten mice C57BL/6 (
 
me
 
v
 
/
 
me
 
v
 
) mice were
obtained from the Jackson Laboratory at 6 wk of age along with
littermate heterozygotes (
 
1
 
/
 
me
 
v
 
) and age-matched wild-type
C57BL/6 (
 
1
 
/
 
1
 
) mice. Motheaten C57BL/6 (
 
me/me
 
) mice and
littermate heterozygotes (
 
1
 
/
 
me
 
) were killed at 4–5 wk of age at
the Jackson Laboratory, and isolated spleen cells were obtained.
 
Antibodies and Flow Cytometry.
 
mAbs to mouse Ly-49A (A1,
mouse IgG2a), NK1.1 (PK136, mouse IgG2a), gp42 (3G7, mouse
IgG2a), and phosphotyrosine (APT) (4G10, mouse IgG2b) were
produced from their respective hybridoma lines. Antibodies were
partially purified from ascites by ammonium sulfate precipitation.
Tissue culture supernatant of anti–mouse Fc receptor antibody
(2.4G2, rat IgG2b) was a gift from P. Linnemeyer (University of
California at San Francisco, CA). Fluorescein conjugation of pro-
tein A-purified mAb utilized standard methods (32). F(ab
 
9
 
)
 
2
 
 frag-
ments were generated by pepsin digestion, and undigested mAb
was absorbed over protein A–Sepharose columns as described
(32). Purity of F(ab
 
9
 
)
 
2
 
 fragments was verified by SDS-PAGE and
silver staining. For fluorescence analysis, mAbs were used at a
concentration of 1 
 
m
 
g/10
 
6
 
 cells. Staining of IL-2–activated NK cells
was performed using directly conjugated mAb in the presence of
blocking antibodies to prevent binding to Fc receptors (1 
 
m
 
g/10
 
6
 
cells mouse IgG2a myeloma antibody [Cappel, Malvern, PA] in
0.1 ml 2.4G2 supernatant). Routine analysis was performed by us-
ing a FACScan
 
Ò
 
.
 
Cytotoxicity Assays.
 
Specific lysis of NK targets was deter-
mined by using a standard 4-h 
 
51
 
Cr-release assay as previously de-
scribed (16). In brief, target cells were harvested and labeled for 1 h
at 37
 
8
 
C with 200 
 
m
 
Ci of sodium 
 
51
 
Cr (Amersham, Arlington
Heights, IL) in complete RPMI. Labeled target cells were washed
and resuspended at 10
 
5
 
 cells/ml, and 0.1 ml of this cell suspension
was added to each well of 96-well plates containing 0.1 ml of ef-
fector cells at the indicated effector to target ratios. Plates were
incubated at 37
 
8
 
C for 4 h, then centrifuged for 5 min. 100 
 
m
 
l of
supernatant was counted in a gamma counter. All assays were per-
formed in triplicate. For antibody inhibition studies, effector cells
were preincubated for 15 min at room temperature with F(ab
 
9
 
)
 
2
 
at a concentration of 50 
 
m
 
g/10
 
6
 
 effectors or with intact antibody
at a concentration of 20 
 
m
 
g/10
 
6
 
 effectors before the addition of
targets.
 
IL-2–activated NK Cells.
 
IL-2–activated NK cells (LAK) were
prepared from fresh splenocytes as previously described (33).
Spleen cells harvested from 
 
me/me
 
 and 
 
1
 
/
 
me
 
 mice were trans-
ported from Jackson Laboratories in complete RPMI, after red
cell lysis, and received within 24 h of death. Spleen cells were
then passaged through nylon wool and placed in culture with IL-2,
as with fresh splenocytes (33). Ly-49A positive and negative IL-2–
activated NK cells were isolated as previously described (6). In
brief, day 6 IL-2–activated NK cells were panned with the anti–
Ly-49A mAb, A1. The purity of the Ly-49
 
2
 
 NK cell population
was ensured by treatment with anti–Ly-49A and rabbit anti–mouse
Ig (Cappel, Malvern, PA), followed by rabbit complement (Ce-
darlane, Westbury, NY) for 1 h at 37
 
8
 
C. Ly-49
 
2
 
 and Ly-49
 
1
 
 cell
populations were then cultured overnight in complete RPMI
supplemented with 1,000 U/ml human IL-2 (National Cancer
Institute, Frederick, MD). Cells were washed extensively with
BSS with 3% FCS on day 7, replated and used for assays on day 9.
This resulted in populations of NK cells that were 
 
.
 
95% pure as
assessed by their expression of NK1.1.
 
cDNA Constructs and Transfections.
 
The construct for expres-
sion of Ly-49A in RNK-16 cells was prepared by subcloning
the Ly-49A cDNA into the EcoRI site of the expression vector
BSR
 
a
 
EN (A. Shaw and M. Olszowy, Washington University, St.
Louis, MO). The Ly-49A/Y8F mutation was generated using site-
directed mutagenesis by PCR with the oligonucleotide 5
 
9
 
-ATA-
TATGAATTCTCGAGATGAGT GAGCAGGAGGTCACTTT-
TTCAATGGTGAG-3
 
9
 
, which was cloned into the EcoRI site
of BSR
 
a
 
EN. Constructs were confirmed by sequencing in both
directions before transfection. Transfections were performed using
cesium-purified plasmids or plasmids purified over two sequential
Qiagen maxiprep tips according to the instructions of the man-
ufacturer (Qiagen, Chadworth, CA). RNK-16 cells in exponen-
tial growth were transfected with 20 
 
m
 
g of ScaI-linearized plasmid
DNA using a BTX-600 Electro Cell manipulator. Electropora-
tion was performed using 3 
 
3
 
 10
 
6
 
 cells/ml in 2-mm cuvettes in a
total volume of 400 
 
m
 
l of complete RPMI, at 115 V, 850 
 
m
 
F,
129 ohms. Cuvettes were incubated on ice for 15 min after elec-
troporation. Cells were cultured overnight, then plated in 96-well
plates at a density of 10
 
4
 
 cells/well in complete RPMI containing
1 mg/ml active G418 (Boehringer, Indianapolis, IN). G418-resis-
tant cells grew out in 10–14 days in 5–10% of the wells. Trans-
fected cells were maintained in 1 mg/ml active G418, but were
grown in complete RPMI without G418 for at least 2 d before
use in functional assays.
 
Measurement of Inositol–Trisphosphate.
 
To measure changes in
water-soluble inositol trisphosphates (InsP
 
3
 
), cells were washed
into inositol-free medium containing [
 
3
 
H]myoinositol (20 
 
m
 
Ci/ml,
80–120 Ci/mmol, Amersham, Arlington Heights, IL) at a con-
centration of 5 
 
3
 
 10
 
6
 
 cells/ml. After incubation at 37
 
8
 
C for 3 h,
cells were washed in complete RPMI. Then 5 
 
3
 
 10
 
6
 
 labeled ef-
fector cells were stimulated with 10
 
7
 
 target cells in a total volume
of 1 ml. Cells were immediately centrifuged at 50 
 
g
 
 for 10 s and
incubated at 37
 
8
 
C for the appropriate interval. [
 
3
 
H]InsP
 
3
 
 was ex-
tracted and resolved by ion exchange chromatography on Dowex
AG-50, 1X-8 (Bio-Rad, Hercules, CA) as previously described (12).
 
Target Stimulation of [
 
32
 
P]-phosphate-labeled Effector Cells.
 
For
 
32
 
P-metabolic labeling, effectors were incubated with 1 mCi/ml
[
 
32
 
P]orthophosphate in phosphate-free RPMI supplemented with
10% dialyzed FCS, at 2 
 
3
 
 10
 
6
 
 cells/ml for 90 min at 37
 
8
 
C. After
labeling, cells were washed once in phosphate-free RPMI and
used immediately for stimulation. In each sample, 10
 
7
 
 labeled ef-
fector cells were stimulated with 10
 
7
 
 unlabeled target cells in a total
volume of 1 ml complete phosphate-free RPMI. Cell suspensions
were immediately centrifuged for 10 s at 50 
 
g
 
, then incubated at 
675
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37
 
8
 
C for the indicated time, after which cells were rapidly centri-
fuged at 500 
 
g
 
 and cell pellets were resuspended in cold HNTG
lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1 mM MgCl
 
2
 
, 10% glycerol, 1 mM sodium orthovanadate, and pro-
tease inhibitors) with 1% Triton X-100. Lysates were precleared
with protein A–Sepharose beads (Pharmacia, Piscataway, NJ) that
had been previously coated with 1 ml 2.4G2 supernatant, for 2 h
at 4
 
8
 
C, then immunoprecipitated with 30 
 
m
 
l of protein A beads
coated with 5 mg APT mAb (4G10) overnight at 4
 
8
 
C. After
washing with cold HNTG buffer with 1% Triton X-100, immu-
noprecipitates were resolved by 8% SDS-PAGE under reducing
conditions. Gels were stained, fixed, and dried, and labeled pro-
teins were resolved by autoradiography.
 
Immunoprecipitations and Western Blotting.
 
Where indicated, trans-
fected  and wild-type RNK-16 cells (1.5 
 
3
 
 10
 
7
 
 cells/ sample)
were incubated for 5 min at 378C in complete RPMI (6 3 105
cells/ml) with 0.03% H2O2 and 100 mM sodium orthovanadate (per-
vanadate), which pharmacologically increases protein tyrosine phos-
phorylation by inhibiting phosphatase activity (34). Cell pellets were
lysed at 48C in complete HNTG lysis buffer containing 1% Tri-
ton X-100. Lysates were precleared for 2 h at 48C on Protein
A–Sepharose beads that had been loaded with 10 mg control mAb
(mouse IgG2a myeloma protein, Cappel, Malvern, PA). Lysates
were then immunoprecipitated overnight at 48C on 30 ml protein
A–Sepharose beads loaded with anti–Ly-49A (A1) or isotype-
matched control mAb (anti-NK1.1). Precipitates were washed
four times with complete HNTG buffer containing 0.1% Triton
X-100. Precipitated samples were resolved by 8% SDS-PAGE
under nonreducing conditions and transferred to PVDF membranes
(Immobilon-P, Millipore, Marlborough, MA). After blocking with
TBS-T (10 mM Tris, pH 8, 150 mM NaCl, 0.05% Tween-20)
and 3% milk, the membranes were incubated with 0.5 mg/ml of
anti–SHP-1 polyclonal rabbit antibody (UBI, Lake Placid, NY) in
TBS–Tween with 3% milk for 1 h at room temperature. After
extensive washing in TBS-T, blots were developed using 125I–pro-
tein A (Amersham, Arlington Heights, IL) followed by autorad-
iography.
Cold-target Inhibition Studies. Cytotoxicity assays to measure
cold-target inhibition were performed at an E/T ratio of 10:1.
105 cold targets were added to effectors at the same time as 104 la-
beled targets. Effectors were preincubated with F(ab9)2 fragments
at 25 mg/106 cells for 15 min at room temperature before addition
of targets when indicated. Results are expressed as percent inhibi-
tion 5 (1 2 [percent cytotoxicity with cold target/percent cyto-
toxicity without cold target]) 3 100. 
Results
Mouse Ly-49A Inhibits Killing of H-2d Targets by RNK-16.
To examine the intracellular signaling pathways that medi-
ate the inhibitory function of mouse Ly-49A, we trans-
fected mouse Ly-49A into RNK-16, a rat cell line with
phenotypic and functional characteristics of rat NK cells
(31). Nine RNK-mLy-49A clones expressing Ly-49A at
different levels were obtained, three of which are repre-
sented in Fig. 1. Clones 2, 8, and 9 are representative of
clones with low, medium, or high expression of Ly-49A,
respectively (Fig. 1, B, C, D). Wild-type RNK-16 effector
cells lysed P388D1 (H-2Dd) tumor cells (Fig. 1 E), but
RNK-16 cells transfected with Ly-49A (RNK-mLy-49A
cells) demonstrated reduced lysis of P388D1 (F, G, H). In-
hibition of lysis of P388D1 cells was proportional to the
level of Ly-49A expression on the RNK-16 transfectants.
RNK-mLy-49A.2 had low expression and demonstrated only
minimal inhibition of lysis (Fig. 1 F), whereas RNK-mLy-
49A.8 and RNK-mLy-49A.9, with progressively higher lev-
els of expression, demonstrated marked inhibition of lysis (G
and H). Inhibition of lysis in Ly-49A transfectants was re-
versible by the addition of anti–Ly-49A F(ab9)2 fragments,
while control F(ab9)2 fragments (anti-NK1.1) had no effect.
Addition of intact antibody had the same effect as F(ab9)2
fragments (data not shown). YAC-1 targets have previously
been shown to be susceptible to lysis by mouse Ly-49A1
NK cells (6). YAC-1 target cells were lysed equally well by
wild-type RNK-16 cells and by RNK-16 cells expressing
Ly-49A at various levels, and lysis of YAC-1 targets was not
altered by the presence of antibodies to Ly-49A (Fig. 1, I–L).
These studies demonstrate that expression of Ly-49A ren-
ders RNK-16 cells ineffective in the killing of H-2Dd tar-
Figure 1. Inhibition of lysis of P388D1 (H-2Dd) targets correlates with
the level of expression of mouse Ly-49A on RNK-16 cells. The various
levels of Ly-49A expression are shown in FACSÒ histograms (A–D). Cells
were incubated with anti–Ly-49A (solid line) with FITC–goat anti–mouse
Ab (FITC–GAM) or FITC-GAM alone (dotted line). Standard 4-h cyto-
toxicity assays were performed with either P388D1 cells (E–H) or YAC-1
targets (I–L). Effectors were wild-type RNK-16 cells (closed symbols) or
RNK-16 transfected with Ly-49A (open symbols). Effector cells used were
RNK-16 (A, E, and I) and clones of RNK-16 expressing Ly-49A: low
expression, RNK-mLy-49A.2 (B, F, J); intermediate expression, RNK-
mLy-49A.8 (C, G, K); and high expression, RNK-mLy-49A.9 (D, H, L).
Assays were carried out in the absence of antibody (squares), or in the
presence of anti-Ly-49A F(ab9)2 ( diamonds) and control F(ab9)2 (anti-
NK1.1) (circles). The dotted line in F–H is the killing curve for wild-type
RNK-16 without mAb (from E for comparison).676 Inhibitory Mechanisms of Ly-49A
gets. The data indicate that the clonal RNK-mLy-49A
transfectants behave similarly to freshly isolated murine Ly-
49A1 NK cells, and that they are a valid model in which to
study Ly-49A function.
Ly-49A Inhibits Phosphoinositide Turnover in Response to
H-2Dd Target Cells. Using the RNK-mLy-49A.9 cell line,
we examined the inositol phosphate response following
stimulation by YAC-1 (sensitive) and P388D1 (resistant)
targets. Wild-type RNK-16, but not RNK-mLy-49A.9
cells, responded to the H-2Dd target P388D1 with a rapid
increase in InsP3 at 2 min, as shown in Fig. 2. YAC-1, which
is susceptible to lysis by both wild-type RNK-16 and
RNK-mLy-49A.9, stimulates an InsP3 response in both cell
types. The lack of phosphoinositide turnover in RNK-
mLy-49A.9 in response to H-2Dd target cells indicates that
Ly-49A interrupts proximal signaling events in RNK-16.
Ly-49A Inhibits an Early Increase in Protein Tyrosine Phos-
phorylation during Target Cell Stimulation. To examine the
effect of Ly-49A–mediated inhibition on protein tyrosine
phosphorylation, [32P]orthophosphate-labeled RNK-16 and
RNK-mLy-49A.9 cells were stimulated with YAC-1 (H-2a)
and P388D1 (H-2Dd) target cells. Because Ly-49A inter-
rupts InsP3 turnover, an early signaling event, we examined
the effect of target stimulation at 30 s, 1 min, and 5 min
time points. Lysates from cells stimulated for these time in-
tervals were immunoprecipitated with APT (4G10) and re-
solved by SDS-PAGE (Fig. 3). RNK-16 cells stimulated
with P388D1 (H-2Dd) showed a rapid increase in protein
tyrosine phosphorylation at 30 s to 1 min, which dimin-
ished toward basal levels at 5 min (Fig. 3, left). In contrast,
RNK-mLy-49A.9 cells stimulated with P388D1 failed to
show an increase in protein tyrosine phosphorylation at 30 s
to 1 min, but showed a minimal increase at 5 min (Fig. 3,
center). Nonetheless, RNK-mLy-49A.9 cells demonstrated
rapid protein tyrosine phosphorylation in response to YAC-1
Figure 2. Ly-49A inhibits phosphoinositide turnover in response to
H-2Dd target cells. RNK-mLy-49A.9 cells fail to generate InsP3 upon
stimulation with P388D1 targets. [3H]myoinositol-labeled RNK-16 and
RNK-mLy-49A.9 effectors (5 3 106 cells) were stimulated with 107 tar-
gets in a total volume of 1 ml at 378C. Soluble InsP3 was resolved by ion
exchange chromatography. A brisk rise in InsP3 was seen in RNK-16
cells (left) in response to either YAC-1 (open squares) or P388D1 (H-2Dd)
(closed circles). Phosphoinositide turnover in RNK-mLy-49A.9 (right) was
stimulated by YAC-1, but not by P388D1.
Figure 3. Ly-49A inhibits an
early rise in tyrosine phosphory-
lation induced by target cell
stimulation. Tyrosine phosphor-
ylation of proteins in RNK-16
cells stimulated with P388D1
cells is shown on the left side of
the figure. RNK-mLy-49A.9
cells stimulated with P388D1
cells are in the center, and
RNK-mLy-49A.9 cells stimu-
lated with YAC-1 cells are on
the right. Target cell stimulation
time points were 0, 0.5, 1.0, and
5.0 min. RNK-16 and RNK-
mLy-49A.9 effector cells were
metabolically labeled with 32P-
orthophosphate. After washing,
107 labeled effector cells and 107
unlabeled target cells were stim-
ulated in a total volume of 1 ml
complete phosphate-free RPMI
with a brief 50 g contact spin,
followed by incubation at 378C
for the indicated time. Cells
were then immediately lysed in
cold HNTG buffer with 1% Tri-
ton X-100. Clarifed precleared
cell lysates were immunoprecipi-
tated with APT (4G10),
washed, and resolved by reduc-
ing 8% SDS-PAGE. Gels were
dried and developed by autorad-
iography.677 Nakamura et al.
after 30 s, demonstrating that this signaling pathway was in-
tact (Fig. 3, right). Wild-type RNK-16 showed a similar re-
sponse to YAC-1 target cells (data not shown). Thus, sus-
ceptible, but not resistant, targets induce very brisk increases
in protein tyrosine phosphorylation, and mouse Ly-49A
specifically interrupts rapid tyrosine phosphorylation in re-
sponse to P388D1 (H-2Dd) targets.
SHP-1 Directly Associates with Mouse Ly-49A. In other
lymphoid cells, SHP-1 has been shown to interrupt early
tyrosine phosphorylation events. The mouse Ly-49A cyto-
plasmic domain includes the proposed SHP-1 binding mo-
tif VxYxxV (21, 22). These structural features of Ly-49A,
and the results obtained in Fig. 3, suggested that Ly-49A–
dependent inhibition of NK cell function might be medi-
ated by SHP-1. Therefore, we first investigated the binding
of SHP-1 to Ly-49A in RNK-16 cells by performing im-
munoprecipitation experiments. RNK-16 and RNK-mLy-
49A.9 cells were stimulated with pervanadate, a phos-
phatase inhibitor that pharmacologically increases protein
tyrosine phosphorylation (34). Lysates from stimulated and
unstimulated cells were precipitated with anti–Ly-49A, and
precipitates were examined for the presence of Ly-49A–asso-
ciated SHP-1 by Western blot analysis. As shown in Fig. 4,
SHP-1 was present only in anti–Ly-49A immunoprecipi-
tates from pervanadate-stimulated RNK-mLy-49A.9 cells.
SHP-1 was not detected in anti–Ly-49A immunoprecipi-
tates from unstimulated RNK-mLy-49A.9 cells or in iso-
type-matched control mAb immunoprecipitates from un-
stimulated or stimulated RNK-mLy-49A.9 cells. SHP-1
was not detected in anti–Ly-49A or control mAb immuno-
precipitates from RNK-16 cells, regardless of stimulation.
Ly-49A Function Is Impaired in NK Cells from Viable Moth-
eaten and Motheaten Mice. To examine the role of SHP-1
in mouse Ly-49A–mediated inhibition, we isolated Ly-
49A1 and Ly-49A2 IL-2–activated NK cells from SHP-1
mutant mice. These included viable motheaten (mev/mev)
mice, which have an incomplete defect in SHP-1, and the
completely SHP-1–deficient motheaten (me/me) mice. We
first examined NK cells from SHP-1 mutant viable moth-
eaten (mev/mev) mice because they survive to 8–9 wk of
age, when NK cell development is complete. These mice
contain a point mutation in the SHP-1 gene that destroys a
donor splice site. This mutation results in aberrant splicing,
creating either an in-frame insertion or deletion in the cat-
alytic domain of the SHP-1 phosphatase (35–37). Although
SHP-1 activity is reduced, some residual SHP-1 function
remains and mev/mev mice have an attenuated motheaten
phenotype.
We isolated Ly-49A1 and Ly-49A2 NK cells from ho-
mozygous mev/mev, heterozygous 1/mev, and wild-type
C57BL/6  1/1 mice. Using these effectors, we tested Ly-
49A function in cytotoxicity assays against C1498 (H-2b)
cells and D12 (C1498.Dd) cells as targets. Ly-49A1 cells
from all mice expressed Ly-49A at similar levels and .95%
of all cells were positive for NK1.1 and negative for CD3
by FACSÒ (data not shown).
In each of four experiments, with homozygous mev/mev
mice the function of Ly-49A was impaired in that C1498.Dd
targets were lysed by Ly-49A1 effectors, albeit less effec-
tively than by Ly-49A2 effectors. However, Ly-49A re-
mained partially effective in cells from mev/mev mice in that
addition of anti–Ly-49A still increased lysis of the C1498.Dd
targets. Fig. 5 shows a representative experiment in which
Ly-49A1 cells from wild-type C57BL/6 1/1 or from het-
erozygous 1/mev mice were unable to lyse C1498.Dd tar-
gets (A and B), but Ly-49A1 cells from homozygous mice
were able to lyse these targets (C). Ly-49A2 cells from all
mice were able to lyse C1498.Dd equally well (Fig. 5, D–F).
Addition of anti–Ly-49A mAb reversed the Ly-49A–medi-
ated inhibition to levels similar to those of Ly-49A2 cells
from all mice, whereas isotype-matched control anti-gp42
mAb had no effect. Ly-49A1 and Ly-49A2 cells from all
Figure 4. The tyrosine phos-
phatase SHP-1 associates with
mouse Ly-49A in pervanadate-
stimulated RNK-16 cells. 1.5 3
107 unstimulated or pervanadate-
stimulated RNK-16 cells or
RNK-mLy-49A.9 cells were in-
cubated in complete RPMI for 5
min at 378C, washed, and lysed
in cold HNTG lysis buffer con-
taining 1% Triton X-100. Clarified
precleared lysates were immuno-
precipitated with anti–Ly-49A
(A1, lanes 5–8) or isotype-
matched control mAb (NK1.1,
PK136, lanes 1–4), washed, and
resolved by 8% SDS-PAGE un-
der nonreducing conditions. Pro-
teins were transferred to PVDF
membranes, immunoblotted with
anti-SHP-1 antiserum, and de-
veloped with 125I–protein A fol-
lowed by autoradiography.678 Inhibitory Mechanisms of Ly-49A
mice were able to lyse the H-2b target C1498 and addition
of mAb anti–Ly-49A or anti-gp42 had no effect (data not
shown). These findings indicate that the function of Ly-
49A is partially impaired in IL-2–activated NK cells iso-
lated from homozygous mev/mev mice.
The partial function of Ly-49A in mev/mev mice could
reflect the residual activity of SHP-1 in these mice. To ex-
amine the effect of the complete absence of SHP-1, we
next examined Ly-49A function in IL-2–activated NK cells
isolated from me/me mice. Using spleen cells harvested from
me/me mice (sacrificed just before their natural demise), 1/me
littermate heterozygote controls, and wild-type 1/1 mice,
we isolated Ly-49A1 and Ly-49A2 cells. As shown in Fig. 6
(B, D, F), Ly-49A expression was equivalent on cells isolated
from all mice. Ly-49A2 cells (Fig. 6, C and E) contained
,5% Ly-49A1 cells, whereas the 1/1 Ly-49A2 popula-
tion (A) contained z10% Ly-49A1 cells. .95% of all cells
were positive for NK1.1 and negative for CD3 by FACSÒ
(data not shown).
As shown in Fig. 7, Ly-49A function was significantly
impaired in NK cells isolated from me/me mice, but, as in
mev/mev mice, it was not completely absent. Ly-49A1 cells
from wild-type 1/1 or from heterozygous 1/me were
unable to lyse C1498.Dd targets (A and B), but Ly-49A1
cells from me/me mice were able to lyse these targets (C),
albeit less effectively than Ly-49A2 cells. Ly-49A2 cells
from all mice were able to lyse C1498.Dd targets equally
well (Fig. 7, D–F). Addition of anti–Ly-49A mAb reversed
Ly-49A–mediated inhibition of Ly-49A1 cells from all mice
(Fig. 7, A–C), whereas control mAb had no effect. Ly-49A1
and Ly-49A2 cells from all mice were able to lyse the H-2b
target C1498 (Fig. 7, G–L), and addition of anti–Ly-49A
or control mAb had no effect. These findings indicate that
Ly-49A is functionally impaired in NK cells isolated from
homozygous me/me mice. However, even in the complete
absence of SHP-1, Ly-49A had some remaining inhibitory
activity.
The Position 8 Tyrosine Is Required for Mouse Ly-49A
Function. To examine further the role of SHP-1 in the
function of Ly-49A, we mutated the tyrosine residue
within the proposed SHP-1 binding motif in the Ly-49A
cytoplasmic domain. RNK-16 cells transfected with this
tyrosine mutant, (RNK-mLy-49A/Y8F) stained with anti–
Ly-49A mAb at levels similar to those seen in RNK-mLy-
49A.9 (Fig. 8, D, F, H). Despite this level of Ly-49A ex-
pression, RNK-mLy-49A/Y8F clones 1 and 4, derived
from separate transfections, were not inhibited in their ca-
pacity to lyse P388D1 (H-2Dd) cells (Fig. 8, E and G). Con-
Figure 5. Ly-49A function is impaired in mev/mev LAK cells. 9-d Ly-49A1
and Ly-49A2 LAK cells were tested in 4-h cytotoxicity assays against D12
(C1498.Dd) targets against Ly-49A1 effector cells (A–C) or Ly-49A2 effec-
tor cells (D–F) from 1/1 (A and D), 1/mev (B and E), or mev/mev mice
(C and F). Assays were done in the absence of antibody (open squares), or
in the presence of anti–Ly-49A (A1, closed diamonds), or isotype-matched
control antibody (anti-gp42, 3G7, open circles).
Figure 6. Ly-49A expression on Ly-49A1 and Ly-49A2 LAK cells iso-
lated from 1/1, 1/me, me/me mice. 6-d LAK cells were separated into
Ly-49A1 and Ly-49A2 populations by panning with anti–Ly-49A Ab.
Ly-49A2 cells were additionally treated with rabbit anti–mouse Ab and
complement depletion. FACSÒ analysis was performed on day 9 LAK cells
using FITC–anti-Ly-49A (A1). Staining was performed in the presence of
unlabeled blocking antibodies (IgG2a mouse myeloma protein, 1 mg/106
cells in 0.1 ml 2.4G2 supernatant). Ly-49A expression is shown in FACSÒ
histograms (A–F). Dotted lines represent cells incubated with saline; solid
lines represent FITC–anti-Ly-49A staining.679 Nakamura et al.
sistent with our earlier results, RNK-mLy-49A.9 cells could
not lyse P388D1 (Fig. 8 C), whereas wild-type RNK-16
lysed P388D1 efficiently (A). Notably, neither anti–Ly-49A
nor control mAb (anti–NK1.1) had any effect on lysis of
P388D1 by RNK-mLy-49A/Y8F (Fig. 8, E and G), but
anti–Ly-49A reversed the inhibition of P388D1 lysis by
RNK-mLy-49A.9 (C). RNK-mLy-49A/Y8F clones 1 and
4 effectively lysed YAC-1 targets (data not shown). These
data show that the tyrosine within the proposed immu-
noreceptor tyrosine-based inhibitory motif (ITIM) is re-
quired for the inhibitory effect of Ly-49A on RNK-16 cy-
totoxicity. These experiments complement the studies of
motheaten mice, demonstrating a functional role for SHP-1
in the inhibitory activity of Ly-49A.
Addition of H-2Dd (Resistant) Targets Does Not Affect the
Killing of Non-H-2Dd (Susceptible) Targets by RNK-mLy-
49A.9. Initial reports demonstrated that ligation of H-2Dd
targets by the Ly-49A receptor resulted in inhibition of natu-
ral killing, of antibody-dependent cellular cytoxicity (ADCC),
and of lectin-induced cytotoxicity by NK cells (6, 38). These
studies, performed on bulk populations of Ly-49A1 NK
cells, suggested that Ly-49A might transduce signals that
globally inhibit NK cell function. Using our RNK-Ly-49A
transfectants, we were able to examine mouse Ly-49A func-
tion in a clonal cell population. To examine the effect of in-
hibitory  H-2Dd targets on the lysis of labeled bystander
non–H-2Dd targets, we performed cold-target competition
experiments with wild-type RNK-16 or RNK-mLy-49A.9
as effectors, and 51Cr-labeled B-16S (H-2b) melanoma tar-
Figure 7. Ly-49A function is impaired in me/me LAK cells. 9-d Ly-49A1
and Ly-49A2 LAK cells were tested in 4-h cytotoxicity assays against D12
(C1498.Dd) and C1498 (H-2b) targets. D12 targets (A–F) and C1498 tar-
gets (G–L) were tested against Ly-49A1 effector cells (A–C and G–I) or
Ly-49A2 effector cells (D–F and J–L) from 1/1 (A, D, G, J), 1/me (B,
E, H, K), or me/me mice (C, F, I, L). Assays were done in the absence of
antibody (open squares), or in the presence of anti–Ly-49A (A1, closed dia-
monds), or isotype-matched control antibody (anti-gp42, 3G7, open circles).
Figure 8. Lysis of P388D1 (H-2Dd) cells is not altered in RNK-mLy-
49A/Y8F transfectants. Ly-49A expression on RNK transfectants was as-
sessed by staining cells with either saline (dotted line) or FITC–anti-Ly-49A
(solid line). FACSÒ histograms show Ly-49A expression in wild-type
RNK-16 (B), RNK-mLy-49A.9 (D), RNK-mLy-49A/Y8F.1 (F) and
RNK-mLy-49A/Y8F.4 (H). Standard 4-h cytotoxicity assays were per-
formed using P388D1 (H-2Dd) as targets. Effector cells were wild-type
RNK-16 (A), RNK-mLy-49A.9 (C), RNK-mLy-49A/Y8F.1 (E), or
RNK-mLy-49A/Y8F.4 (G). Effectors were preincubated with either me-
dia alone (open squares), anti-Ly-49A (closed circles), or isotype-matched
control antibody (anti-NK1.1, PK136, closed triangles), before addition of
targets.680 Inhibitory Mechanisms of Ly-49A
get cells. The effect of unlabeled H-2Dd or non–H-2Dd
targets on lysis of B-16S was determined for each effector
(Fig. 9). As expected, unlabeled B-16S (H-2b) were effec-
tive cold-target competitors for the lysis of 51Cr-labeled
B-16S by both RNK-16 and by RNK-mLy-49A.9. Unla-
beled P388D1 (H-2Dd) targets, which are sensitive to lysis
by RNK-16, effectively inhibited B-16S lysis by RNK-16.
In contrast, P388D1, which was not killed by RNK-mLy-
49A.9, was relatively ineffective as a cold-target inhibitor of
B-16S lysis by RNK-mLy-49A.9. In the presence of F(ab9)2
anti–Ly-49A, P388D1 became sensitive to lysis by RNK-
mLy-49A.9. This allowed cold P388D1 cells to compete
effectively with labeled B-16S for the lytic machinery of
RNK-mLy-49A.9. Control F(ab9)2 anti-NK1.1 fragments
had no effect on cold-target competition.
Thus, the expression of H-2Dd on bystander targets does
not globally inhibit the Ly-49A1 effector cell response to-
wards a non–H-2Dd cell. Rather, because H-2Dd cells are
not susceptible to NK cell lysis by Ly-49A1 effectors, they
compete less well than susceptible (B-16S) cold targets for
the lysis of labeled B-16S. These data indicate that there is
no bystander inhibition through Ly-49A. They suggest that
inhibitory effects mediated through this receptor are spa-
tially oriented toward ligand-bearing H-2Dd targets on the
NK cell membrane, and this does not affect killing of sus-
ceptible targets recognized by the same NK cell. Alterna-
tively, the duration of Ly-49A–mediated inhibition could
be brief, and temporally limited to periods of NK cell con-
tact with H-2Dd targets. Temporal restriction would allow
the subsequent lysis of susceptible H-2b targets by the same
NK cell.
Discussion
In an attempt to elucidate the pathways through which
Ly-49 molecules inhibit natural killing, we examined mouse
Ly-49A, which prevents NK cell lysis of targets expressing
H-2Dd or H-2Dk (6). To study Ly-49A function in a uni-
form clonal NK cell population, we transfected the rat NK
cell line RNK-16 with the mouse Ly-49A cDNA. Ly-49A
was functional in these RNK-16 transfectants, specifically
inhibiting lysis of the H-2Dd target P388D1.
Because activation of cytotoxicity is associated with phos-
phoinositide turnover and an increase in protein tyrosine
phosphorylation in NK cells, we examined the effect of
Ly-49A ligation on these early signaling events during
target-induced NK cell activation. Rapid rises in InsP3
were stimulated in wild-type RNK-16 cells in response to
P388D1 (H-2Dd) targets, but the expression of Ly-49A on
RNK-16 cells prevented this response. Ligation of Ly-49A
also inhibited target cell–induced protein tyrosine phos-
phorylation in response to P388D1 targets. In contrast,
YAC-1 targets stimulated a prompt increase in protein ty-
rosine phosphorylation in wild-type RNK-16 cells and in
RNK-mLy-49A.9 cells.
The ability of mouse Ly-49A to inhibit the generation of
InsP3 is similar to the effect previously shown in human
NK cells, where inhibition of inositol phosphate turnover
parallels the inhibition of NK cell cytotoxicity by class I
molecules (39). Although no crosshybridizing human Ly-49
homologues have yet been identified, human NK cells ex-
press a different family of KIRs (40). The structure of KIRs,
which are type I immunoglobulin-like receptors, is not re-
lated to that of Ly-49A. However, like Ly-49A, the KIRs
inhibit NK cell cytotoxicity upon ligation by specific MHC
class I antigens on target cells (41–46).
Initial reports of human NK cells indicated that protein
tyrosine phosphorylation was not inhibited by the expres-
sion of MHC class I on targets (29, 39). One study exam-
ined target-induced phosphorylation in NK cells stimulated
for 1, 5, and 30 min, and another study examined NK cells
stimulated for 5 min (29, 39). In these human studies, there
were no appreciable differences in levels of phosphoryla-
tion when NK cells were stimulated with susceptible or re-
sistant targets. In our RNK-mLy-49A.9 transfectant, we
also could detect no significant differences in protein ty-
rosine phosphorylation at 5 min (Fig. 3), or at 15 and 30
min (data not shown) after target cell stimulation with ei-
ther sensitive or resistant targets. However, we were able to
demonstrate clearly that rapid (30–60 s) protein tyrosine
phosphorylation is markedly reduced when Ly-49A medi-
ates inhibition of cytotoxicity. The inhibitory effects of Ly-
49A on phosphoinositide turnover and on tyrosine phos-
phorylation indicate that Ly-49A interrupts signaling events
early in target cell–induced activation of NK cells.
A possible mechanism for the inhibitory activity of Ly-
Figure 9. Cold-target competition of unlabeled P388D1 and B-16S in
the lysis of labeled B-16S targets. 4-h cytotoxicity assays were performed
with RNK-16 (left) or RNK-mLy-49A.9 cells (right) as effectors. B-16S
(H-2b) target cells were labeled with 51Cr and tested at an effector to la-
beled target ratio of 10:1. Cold targets were either unlabeled B-16S cells
(H-2b) or P388D1 cells (H-2Dd). Cold targets were added in 10-fold ex-
cess to labeled targets. 105 cold targets and 104 labeled targets were added
at the same time to 105 effectors in a total volume of 0.2 ml. Effectors
were preincubated with no antibody, F(ab9)2 anti–Ly-49A or F(ab9)2 anti-
NK1.1. Results are expressed as percent inhibition 5 (1 2 [percent cyto-
toxicity with cold target/percent cytotoxicity without cold target]) 3 100.681 Nakamura et al.
49A was suggested by the observation that several other in-
hibitory receptors bind to SHP-1, a cytoplasmic tyrosine
phosphatase (47–50). In other hematopoetic cells, SHP-1
has been implicated in the downregulation of signals for
cellular activation. Thus, SHP-1 inhibits activation through
the erythropoietin receptor, and erythropoietin receptors
mutated at the SHP-1 binding site exhibit prolonged acti-
vation in response to ligand (23, 24). In B cells, activation
through the immunoglobulin receptor is inhibited by coli-
gation with FcgRIIB1 and this effect correlates with SHP-1
binding to FcgRIIB1 (25–28). SHP-1 binding has also been
correlated with inhibition of human NK cell function (21,
29, 30). The KIRs associate with SHP-1 in human NK
cells (21, 29, 30), and expression of a dominant negative
mutant SHP-1 molecule in a human NK clone inhibits KIR
function (21). Thus, in NK cells and in other immune cells,
SHP-1 has been functionally implicated in the inhibition of
cellular activation signals.
Because of this inhibitory effect, the binding domains for
SHP-1 on immune receptors have been termed ITIMs.
As originally proposed, the ITIM motif was described as
S/TxxYxxL (25), but the KIR motifs are V/IxYxxL, and
phosphopeptides containing this motif have been shown to
bind to SHP-1 (21, 22, 29). Similar motifs, constrained by
the sequence VxYxxV/L are found in Ly-49A, in the in-
hibitory receptors Ly-49C and Ly-49G2, and in the func-
tionally uncharacterized murine molecules Ly-49B, E, F,
G1, and G3. Interestingly, mouse Ly- 49D, which has been
implicated in NK cell activation (rather than inhibition),
lacks an ITIM motif as does the functionally uncharacterized
molecule Ly-49H (2, 5, 51). Previous studies by Olcese et al.
(22) showed that a synthetic, tyrosine-phosphorylated, 13-
amino acid peptide derived from the mouse Ly-49A cyto-
plasmic domain binds SHP-1 in vitro. In the present exper-
iments, we have demonstrated that intact mouse Ly-49A
also binds to SHP-1 in pharmacologically stimulated RNK-
16 transfectants.
In mouse NK cells, we examined the functional impor-
tance of the Ly-49A/SHP-1 association. To clarify the role
of SHP-1 in NK cell inhibition through Ly-49A, we ex-
amined NK cells from viable motheaten (mev/mev) and moth-
eaten (me/me) mice. Consistent with previous reports, the
lysis of YAC-1 targets by mev/mev or me/me NK cells was
somewhat diminished compared with lysis by wild-type,
heterozygous (1/mev or 1/me) NK cells (data not shown)
(52). However, lysis of C1498 target cells by mev/mev or
me/me NK cells was essentially normal. When compared
with C1498 (H-2b), lysis of D12 (C1498.Dd) was almost
completely inhibited by Ly-49A in NK cells from wild-
type or from heterozygous (1/mev or 1/me) mice. By con-
trast, Ly-49A-mediated inhibition of C1498.Dd lysis in
both mev/mev and me/me NK cells was significantly im-
paired. We initially thought that incomplete impairment of
Ly-49A function in mev/mev mice might be due to the in-
complete loss of SHP-1 activity in these mice. However,
Ly-49A also retained partial activity in NK cells from me/me
mice, which are completely deficient in SHP-1. This im-
plies that other cytoplasmic mediators must also be capable
of facilitating inhibition by Ly-49A. One candidate media-
tor is the structurally related tyrosine phosphatase SHP-2,
which, like SHP-1, has been shown to bind to a tyrosine-
phosphorylated peptide containing the ITIM of Ly-49A
(22). SHP-2 has recently been shown to associate with the
CTLA-4 receptor on T cells, suggesting a role for SHP-2
in the down regulation of T cell activation (53). In support
of a role for SHP-2, we have recently been able to demon-
strate an association between intact Ly-49A and SHP-2 in
anti–Ly-49A immunoprecipitates from pervanadate-stimu-
lated RNK-mLy-49A cells (data not shown).
Site-directed mutational analysis of the Ly-49A molecule
confirmed the functional significance of the Ly-49A/SHP-1
interaction. Disruption of the putative ITIM motif in Ly-
49A by mutating the tyrosine to phenylalanine at residue 8
(Y8F), completely eliminated Ly-49A–mediated inhibition of
cytotoxicity against H-2Dd target cells by RNK-16 trans-
fectants.
Our studies demonstrate that Ly-49A interrupts proxi-
mal signaling events during natural killing, and they pro-
vide evidence that this inhibitory function is largely medi-
ated through the SHP-1 phosphatase. The mechanisms by
which SHP-1 inhibits cytotoxicity have not been fully elu-
cidated. Our cold-target inhibition studies suggest that the
Ly-49A–mediated inhibitory effect is localized within the
NK cell, because targets expressing H-2Dd are protected
from lysis but fail to inhibit NK cell cytotoxicity against
non–H-2Dd targets. Thus, Ly-49A does not transduce glo-
bal inhibitory signals to NK cells. Rather, it appears that
Ly-49A may locally interrupt activating signals transduced
by other receptors during natural killing.
In summary, we have demonstrated that the ligation of
Ly-49A by its MHC class I ligand, H-2Dd, interrupts early
signaling events stimulated during target-induced activation
of NK cells, including phosphoinositide turnover and pro-
tein tyrosine phosphorylation. We have also shown the di-
rect association of the cytoplasmic tyrosine phosphatase SHP-1
with Ly-49A. Our studies indicate a requirement for SHP-1
for the optimal function of Ly-49A, as we found that Ly-
49A function is markedly impaired in SHP-1 mutant mev/mev
and me/me mice. The finding of partial Ly-49A function
despite the complete absence of SHP-1 in me/me mice in-
dicates the possible involvement of other cytoplasmic me-
diators, such as SHP-2. In addition, we have shown that
the tyrosine within the proposed SHP-1 binding motif in
Ly-49A is strictly required for the inhibitory effects of this
receptor on cytotoxicity. Finally, we have demonstrated
that inhibition through Ly-49A is target specific. Although
a number of candidate activating receptors on NK cells
have been described, including the lectin-like NKR-P1
molecule (54), the specific receptors that bind tumors and
activate NK cell cytotoxicity have not yet been identified.
Our studies indicate that the inhibitory Ly-49A receptor
interrupts target-induced activation signals through its re-
cruitment of inhibitory mediators to the effector/target in-
terface in a spatially or temporally restricted manner.682 Inhibitory Mechanisms of Ly-49A
References
1. Yokoyama, W.M., and W.E. Seaman. 1993. The Ly-49 and
NKR-P1 gene families encoding lectin-like receptors on nat-
ural killer cells: The NK gene complex. Annu. Rev. Immunol.
11:613-635.
2. Smith, H.R.C., F.M. Karlhofer, and W.M. Yokoyama. 1994.
Ly-49 multigene family expressed by IL-2-activated NK
cells.  J. Immunol. 153:1068–1079.
3. Yokoyama, W.M., L.B. Jacobs, O. Kanagawa, E.M. Shevach,
and D.I. Cohen. 1989. A murine T lymphocyte antigen be-
longs to a supergene family of type II integral membrane pro-
teins. J. Immunol.  143:1379–1386.
4. Wong, S., J.D. Freeman, C. Kelleher, D. Mager, and F.
Takei. 1991. Ly-49 multigene family: new members of a su-
pergene family of type II membrane proteins with lectin-like
domains. J. Immunol.  147:1417–1423.
5. Brennan, J., D. Mager, W. Jefferies, and F. Takei. 1994. Ex-
pression of different members of the Ly-49 gene family de-
fines distinct natural killer cell subsets and cell adhesion prop-
erties. J. Exp. Med. 180:2287–2295.
6. Karlhofer, F.M., R.K. Ribaudo, and W.M. Yokoyama. 1992.
MHC class I alloantigen specificity of Ly-491 IL-2-activated
natural killer cells. Nature (Lond.). 358:66–70.
7. Stoneman, E.R., M. Bennett, J. An, K.A. Chesnut, E.K.
Wakeland, J.B. Scheerer, M.J. Siliciano, V. Kumar, and P.A.
Matthew. 1995. Cloning and characterization of 5E6 (Ly-
49C), a receptor expressed on a subset of murine natural
killer cells. J. Exp. Med. 182:305–313.
8. Mason, L.H., J.R. Ortaldo, H.A. Young, V. Kumar, M. Ben-
nett, and S.K. Anderson. 1995. Cloning and functional char-
acteristics of murine LGL-1: A member of the Ly-49 gene
family (Ly-49G2). J. Exp. Med. 182:293–303.
9. Daniels, B.F., F.M. Karlhofer, W.E. Seaman, and W.M.
Yokoyama. 1994. A natural killer cell receptor specific for a
major histocompatibility complex class I molecule. J. Exp.
Med. 180:687–692.
10. Kane, K.P. 1994. Ly-49 mediates EL-4 lymphoma adhesion
to isolated class I major histocompatibility complex mole-
cules.  J. Exp. Med. 179:1011–1015.
11. Giorda, R., and M. Trucco. 1991. Mouse NKR-P1. A fam-
ily of genes selectively co-expressed in adherent lymphokine-
activated killer cells. J. Immunol. 147:1701–1708.
12. Ryan, J.C., J. Turck, E.C. Niemi, W.M. Yokoyama, and
W.E. Seaman. 1992. Molecular cloning of the NK1.1 anti-
gen, a member of the NKR-P1 family of natural killer cell
activation molecules. J. Immunol. 149:1631–1635.
13. Yokoyama, W.M., J.C. Ryan, J.J. Hunter, H.R.C. Smith,
M. Stark, and W.E. Seaman. 1991. cDNA cloning of mouse
NKR-P1 and genetic linkage with Ly-49: identification of a
natural killer cell gene complex on mouse chromosome 6. J.
Immunol. 147:3229–3236.
14. Karlhofer, F.M., and W.M. Yokoyama. 1991. Stimulation of
murine natural killer (NK) cells by a monoclonal antibody
specific for the NK1.1 antigen: IL-2-activated NK cells pos-
sess additional specific stimulation pathways. J. Immunol. 146:
3662–3673.
15. Chambers, W.H., N.L. Vujanovic, A.B. DeLeo, M.W.
Olszowy, R.B. Herberman, and J.C. Hiserodt. 1989. Mono-
clonal antibody to a triggering structure expressed on rat nat-
ural killer cells and adherent lymphokine-activated killer cells.
J. Exp. Med. 169:1373–1389.
16. Ryan, J.C., E.C. Niemi, R.D. Goldfien, J.C. Hiserodt, and
W.E. Seaman. 1991. NKR-P1, an activating molecule on rat
natural killer cells, stimulates phosphoinositide turnover and a
rise in intracellular calcium. J. Immunol. 147:3244–3250.
17. Seaman, W.E., E. Eriksson, R. Dobrow, and J.B. Imboden.
1987. Inositol trisphosphate is generated by a rat natural killer
cell tumor in response to target cells or to crosslinked mono-
clonal antibody OX-34: Possible role for the OX-34 deter-
minant during activation by target cells. Proc. Natl. Acad. Sci.
USA. 84:4239–4243.
18. Cassatella, M.A., I. Anegón, M.C. Cuturi, P. Griskey, G.
Trinchieri, and B. Perussia. 1989. FcgR(CD16) interaction
with ligand induces Ca21 mobilization and phosphoinositide
turnover in human natural killer cells. Role of Ca21 in Fc
gamma R (CD16)-induced transcription and expression of
lymphokine genes. J. Exp. Med. 1169:549–567.
19. Einspahr, K.J., R.T. Abraham, B.A. Binstadt, Y. Uehara, and
P.J. Leibson. 1991. Tyrosine phosphorylation provides an
early and requisite signal for the activation of natural killer
cell function. Proc. Natl. Acad. Sci. USA.  88:6279–6283.
20. O’Shea, J.J., D.W. McVicar, D.B. Kuhns, and J.R. Ortaldo.
1992. A role for protein tyrosine kinase activity in natural cy-
totoxicity as well as antibody-dependent cellular cytotoxicity.
Effects of herbimycin A. J. Immunol. 148:2497–2502.
We thank F.M. Karlhofer and W. Yokoyama for providing important reagents that enabled these studies, M.
Olszowy and A. Shaw for the BSRa vector and invaluable help with transfection of RNK-16, S. Christian-
son for preparing me/me splenocytes, D.A. Lacy for assistance with the viable motheaten studies, E. Gum for
sequencing, and T.P. Quinn for helpful discussions.
This work was supported by the Veterans Administration and National Institutes of Health grant RO1
CA69299 (W.E. Seaman). J.C. Ryan is the recipient of National Institutes of Health grant R29 CA60944
and is supported by the International Human Frontiers in Science program. M.C. Nakamura is supported by
National Institutes of Health grant K11 AR01927, the Rosalind Russell Arthritis Foundation, and Multipur-
pose Arthritis Center grant P60AR20684. L.D. Shultz is the recipient of National Institutes of Health grant
RO1 CA20408.
Address correspondence to Dr. Mary Nakamura, Immunology/Arthritis Section 111-R, Veterans Adminis-
tration Medical Center, 4150 Clement Street, San Francisco, California 94121.
Received for publication 17 October 1996 and in revised form 26 December 1996.683 Nakamura et al.
21. Burshtyn, D.N., A.M. Scharenberg, N. Wagtmann, S. Raja-
gopalan, K. Berrada, T. Yi, J.-P. Kinet, and E.O. Long. 1996.
Recruitment of tyrosine phosphatase HCP by the killer cell
inhibitory receptor. Immunity. 4:77–85.
22. Olcese, L., P. Lang, F. Vely, A. Cambiaggi, D. Marguet, M.
Blery, K.L. Hippen, R. Biassoni, A. Moretta, L. Moretta,
J.C. Cambier, and E. Vivier. 1996. Human and mouse killer
cell inhibitory receptors recruit PTP-1C and PTP-1D pro-
tein tyrosine phosphatases. J. Immunol. 156:4531–4534.
23. Klingmuller, U., U. Lorenz, L.C. Cantley, B.G. Neel, and
H.F. Lodish. 1995. Specific recruitment of SH-PTP1 to the
erythropoietin receptor causes inactivation of JAK2 and ter-
mination of proliferative signals. Cell. 80:729–38.
24. Yi, T., J. Zhang, O. Miura, and J.N. Ihle. 1995. Hematopoi-
etic cell phosphatase associates with erythropoietin (Epo) re-
ceptor after Epo-induced receptor tyrosine phosphorylation:
identification of potential binding sites. Blood. 85:87–95.
25. Thomas, M.L. 1995. Of ITAMS and ITIMS: turning on and
off the B cell antigen receptor. J. Exp. Med. 181:1953–1956.
26. Muta, T., T. Kurosaki, Z. Misulovin, M. Sanchez, M.C.
Nussenzwig, and J.V. Ravetch. 1994. A 13-amino-acid motif
in the cytoplasmic domain of Fc gamma RIIB modulates B-cell
receptor signalling. Nature (Lond.). 368:70–73.
27. D’Ambrosio, D., K.L. Hippen, S.A. Minskoff, I. Mellman,
G. Pani, K.A. Siminovitch, and J.C. Cambier. 1995. Re-
cruitment and activation of PTP-1C in negative regulation of
antigen receptor signaling by FcgRIIB1. Science (Wash. DC).
268:293–297.
28. Pani, G., M. Kozlowski, J.C. Cambier, G.B. Mills, and K.A.
Siminovitch. Identification of the tyrosine phosphatase
PTP1-C as a B cell antigen receptor–associated protein in-
volved in the regulation of B cell signaling. J. Exp. Med. 181:
2077–2084.
29. Campbell, K.S., M. Dessing, M. López-Botet, M. Cella, and
M. Colonna. 1996. Tyrosine phosphorylation of a human
killer inhibitory receptor recruits protein tyrosine phos-
phatase 1C. J. Exp. Med. 184:93–100.
30. Fry A., L.L. Lanier, and A. Weiss. 1996. Phosphotyrosines in
the KIR motif of NKB1 are required for negative signaling
and for association with PTP-1C. J. Exp. Med. 184:295–300.
31. Reynolds, C.W., E.W. Bere, Jr., and J.M. Ward. 1984. Nat-
ural killer activity in the rat. III. Characterization of trans-
plantable large granular lymphocyte (LGL) leukemias in the
F344 rat. J. Immunol. 132:534–540.
32. Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. She-
vach, and W. Strober, editors. 1992. In Current Protocols in
Immunology. John Wiley and Sons, New York.
33. Vujanovic, N.L., R.B. Herberman, A.A. Maghazachi, and
J.C. Hiserodt. 1988. Lymphokine-activated killer cells in rats.
III. A simple method for the purification of large granular
lymphocytes and their rapid expansion and conversion into
lymphokine-activated killer cells. J. Exp. Med.  167:15–29.
34. O’Shea, J.J., D.W. McVicar, T.L. Bailey, C. Burns, and M.J.
Smith. 1992. Activation of human peripheral blood T lympho-
cytes by pharmacologic induction of protein-tyrosine phos-
phorylation. Proc. Natl. Acad. Sci. USA. 89:10306–10310.
35. Shultz, L.D., P.A. Schweitzer, T.V. Rajan, T. Yi, J.N. Ihle,
R.J. Matthews, M.L. Thomas, and D.R. Beier. 1993. Muta-
tions at the motheaten locus are within the hematopoietic
cell protein-tyrosine phosphatase (Hcph) gene. Cell. 73:1445–
1454.
36. Kozlowski, M., I. Mlinaric-Rascan, G.S. Feng, R. Shen, A.
Pawson, and K.A. Siminovitch. 1993. Expression and cata-
lytic activity of the tyrosine phosphatase PTP1C is severely im-
paired in motheaten and viable motheaten mice. J. Exp. Med.
178:2157–2163.
37. Tsui, H.W., K.A. Siminovitch, L. de Souza, and F.W.L.
Tsui. 1993. Motheaten and viable motheaten mice have mu-
tations in the hematopoietic cell phosphatase gene. Nature
Genet. 4:124–129.
38. Karlhofer, F.M., R.K. Ribaudo, and W.M. Yokoyama. 1992.
The interaction of Ly-49 with H-2Dd globally inactivates
NK cell cytolytic activity. Trans. Assoc. Am. Phys. 105:72–85.
39. Kaufman, D.S., R.A. Schoon, M.J. Robertson, and P.J. Lieb-
son. 1995. Inhibition of selective signaling events in natural
killer cells recognizing major histocompatibility complex class
I. Proc. Natl. Acad. Sci. USA. 92:6484–6488.
40. Lanier, L.L., and J.H. Phillips. 1996. Inhibitory MHC class I
receptors on NK cells and T cells. Immunol. Today. 17:86–91.
41. Moretta, A., M. Vitale, C. Bottino, A.M. Orengo, L. Morelli,
R. Augugliaro, M. Barbaresi, E. Ciccone, and L. Moretta.
1993. p58 molecules as putative receptors for major histo-
compatibility complex (MHC) class I molecules in human
natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis
of MHC class I–protected cells in NK clones displaying dif-
ferent specificities. J. Exp. Med. 178:597–604.
42. Litwin,V., J. Gumperz, P. Parham, J.H. Phillips, and L.L.
Lanier. 1994. NKB1: a natural killer cell receptor involved in
the recognition of polymorphic HLA-B molecules. J. Exp.
Med. 180:537–543.
43. Wagtmann, N., S. Rajagopalan, C.C. Winter, M. Peruzzi,
and E.O. Long. 1995. Killer cell inhibitory receptors specific
for HLA-C and HLA-B identified by direct binding and by
functional transfer. Immunity.  3:801–809.
44. Colonna, M., and J. Samaridis. 1995. Cloning of Ig-super-
family members associated with HLA-C and HLA-B recog-
nition by human NK cells. Science (Wash. DC). 268:405–408.
45. D’Andrea, A., C. Chang, K. Franz-Bacon, T. McClananhan,
J.H. Phillips, and L.L. Lanier. 1995. Molecular cloning of
NKB1, a natural killer cell receptor for HLA-B allotypes. J.
Immunol. 155:2306–2310.
46. Moretta, A., S. Sivori, M. Vitale, D. Pende, L. Morelli, R.
Augugliaro, C. Bottino, and L. Moretta. 1995. Existence of
both inhibitory (p58) and activatory (p50) receptors for
HLA-C molecules in human natural killer cells. J. Exp. Med.
182:875–884.
47. Shen, S.-H., L. Bastien, B.I. Posner, and P. Chretien. 1991.
A protein-tyrosine phosphatase with sequence similarity to
the SH2 domain of the protein-tyrosine kinases. Nature
(Lond.). 352:736–739.
48. Yi, T., J.L. Cleveland, and J.N. Ihle. 1992. Protein tyrosine
phosphatase containing SH2 domains: characterization, pref-
erential expression in hemopoietic cells and localization to
human chromosome 12p12–p13. Mol. Cell. Biol. 12:2386–
2405.
49. Plutzsky, J., B.G. Neel, and R.D. Rosenberg. 1992. Isolation
of a src homology 2 containing tyrosine phosphatase. Proc.
Natl. Acad. Sci. USA.  89:1123–1127.
50. Matthew, R.J., D.B. Bowne, E. Flores, and M.L. Thomas.
1992. Characterization of hematopoietic intracellular protein
tyrosine phosphatase: description of a phosphatase containing
an SH2 domain and another enriched in proline-, glutamic
acid- , serine- and threonine-rich sequences. Mol. Cell. Biol.
12:2396–2405.
51. Mason, L.H., S.K. Anderson, H.R.C. Smith, W.M.
Yokoyama, and J.R. Ortaldo. 1995. Recognition and poten-684 Inhibitory Mechanisms of Ly-49A
tial triggering of Ly-49D1 NK cells by monoclonal antibody
12A8. Natural Immunity. 14:95.
52. Koo, G.C., C.L. Manyak, J. Dasch, L. Ellingsworth, and L.D.
Shultz. 1991. Suppressive effects of monocytic cells and trans-
forming growth factor-beta on natural killer cell differentia-
tion in autoimmune viable motheaten mutant mice. J. Immu-
nol. 147:1194–1200.
53. Marengère, L.E.M., P. Waterhouse, G.S. Duncan, H.W.
Mittrücker, G.S. Feng, and T.W. Mak. 1996. Regulation of
T cell receptor signaling by tyrosine phosphatase SYP associ-
ation with CTLA-4. Science (Wash. DC). 272:1170–1173.
54. Ryan, J.C., E.C. Niemi, M.C. Nakamura, and W.E. Seaman.
1995. NKR-P1A is a target specific receptor that activates
natural killer cell cytotoxicity. J. Exp. Med. 181:1911–1915.